ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia, miR-212 inhibition resulted in ABCG2 (ABC Subfamily G Member 2) upregulation and increased ABCG2-dependent efflux of Imatinib [16].